Pharmaron (03759.HK) reported a net profit attributable to shareholders of RMB 1.247 billion for the first three quarters, up 9.31% year on year.

Zhitong Finance APP news, Pharmaron (03759.HK) released its performance for the first three quarters of 2026. The Group achieved operating revenue of RMB 12.003 billion, a year-on-year increase of 19.01%; net profit attributable to shareholders of the listed company was RMB 1.247 billion, a year-on-year increase of 9.31%; basic earnings per share were RMB 0.6862.